Erik van Werkhoven
15PUBLICATIONS
88CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (15)
Sort by Publication Date:
|Dec 12, 2025
Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma.Steven Wang, Marcel Nijland, Leonie Strobbe
|Jan 08, 2024
Distinct peripheral T-cell and NK-cell profiles in HGBL-MYC/BCL2 vs patients with DLBCL NOS.A Vera de Jonge, Carolien Duetz, Wassilis S C Bruins
|Sep 09, 2023
High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial.Sonja Vliek, Florentine S Hilbers, Erik van Werkhoven
|May 22, 2023
A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients.A Vera de Jonge, Erik van Werkhoven, Avinash G Dinmohamed
|Jan 20, 2022
Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment.Louisa R Hoes, Jade M van Berge Henegouwen, Hanneke van der Wijngaart
|Dec 30, 2021
Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments.Lennart Kester, Danielle Seinstra, Annelot G J van Rossum
Pageof 3
Frequent Collaborators
3 joint publications
Daphne van der Velden
3 joint publications
Marleen Kok
3 joint publications
Nicola S Russell
3 joint publications
Jelle Wesseling
3 joint publications
Hugo M Horlings
2 joint publications
Karin E de Visser
2 joint publications
Ton N Schumacher
2 joint publications
Petra Nederlof
2 joint publications
John B A G Haanen
2 joint publications
Koen K van de Vijver
